CytomX Therapeutics Inc (NASDAQ:CTMX) CFO Debanjan Ray sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $22.39, for a total value of $67,170.00. Following the completion of the sale, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at $199,897.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Debanjan Ray also recently made the following trade(s):
- On Wednesday, August 1st, Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock. The stock was sold at an average price of $26.05, for a total value of $78,150.00.
- On Monday, July 2nd, Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock. The stock was sold at an average price of $22.56, for a total value of $67,680.00.
Shares of NASDAQ:CTMX traded down $0.03 during midday trading on Friday, reaching $20.14. 338,960 shares of the company’s stock were exchanged, compared to its average volume of 276,447. The company has a market capitalization of $906.92 million, a price-to-earnings ratio of -17.36 and a beta of 0.81. CytomX Therapeutics Inc has a fifty-two week low of $16.19 and a fifty-two week high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The business had revenue of $21.34 million for the quarter, compared to analyst estimates of $16.48 million. CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. sell-side analysts expect that CytomX Therapeutics Inc will post -1.5 EPS for the current year.
A number of analysts have issued reports on the company. ValuEngine downgraded CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 29th. BidaskClub downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. SunTrust Banks assumed coverage on CytomX Therapeutics in a research note on Friday, June 1st. They issued a “buy” rating and a $38.00 target price for the company. Finally, Cantor Fitzgerald set a $40.00 target price on CytomX Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $38.38.
Large investors have recently modified their holdings of the stock. Great West Life Assurance Co. Can increased its position in shares of CytomX Therapeutics by 174.6% during the 2nd quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 3,143 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $119,000. WINTON GROUP Ltd acquired a new stake in shares of CytomX Therapeutics during the 1st quarter worth about $205,000. Xact Kapitalforvaltning AB acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $206,000. Finally, First Republic Investment Management Inc. acquired a new stake in shares of CytomX Therapeutics during the 1st quarter worth about $216,000. 72.16% of the stock is owned by hedge funds and other institutional investors.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: NASDAQ Stock Market Explained
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.